This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Short-term effects of intravitreal bevacizumab on the cornea

Short-term effects of intravitreal bevacizumab on the cornea
Reviewed by Khadijah Basheer

1 December 2014 | Khadijah Basheer | EYE - Cornea, EYE - General | anterior chamber depth, bevacizumab, central corneal thickness, intraocular pressure, iridocorneal angle, simulated keratometry

Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may have on the cornea as there is little known about potential corneal toxicity compared to the retina. A higher dose of bevacizumab, 2.5mg/0.1ml was injected intravitreally into 43 eyes. The subjects and a control group were studied for one month and the following measurements were taken: central corneal thickness, intraocular pressure, simulated keratometry, anterior chamber depth and iridocorneal angle. No side-effects or corneal endothelial toxicity was observed and after one month there was no statistical difference in any of the above measurements. The authors conclude from this short study that a one off dose of intravitreal bevacizumab has no toxic effects on the cornea. However, the follow-up period was only one month, we do not know whether any later effects become apparent after one month, what occurs after multiple injections of bevacizumab or the effects of injecting bevacizumab into the cornea itself. More research into this area is needed to provide further confidence regarding the safety of bevacizumab on the cornea and anterior chamber structures.

Short term effects of intravitreal bevacizumab on the cornea.
Guler M, Capkin M, Simsek A, et al.
CURRENT EYE RESEARCH
2014;39(10):989-93.
Share This
CONTRIBUTOR
Khadijah Basheer

Moorfields Eye Hospital, London, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency